Can immune fingerprints unlock new treatments for skin disease?
NCT ID NCT07771673
First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time
Summary
This observational study aims to map the immune and molecular profiles of people with inflammatory skin conditions, including genetic forms like epidermolysis bullosa. By comparing these profiles to those of healthy individuals, researchers hope to identify unique signatures that could point to new therapeutic targets. The study also tracks how these signatures change after systemic therapy and aims to build a bioresource for future skin disease research.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could reveal new therapeutic targets for inflammatory skin diseases and create a valuable resource for future research.
- What could go wrong
- As an observational study, it won't test treatments directly. Findings may not translate into therapies, and the diversity of skin conditions could make broad conclusions challenging.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 400 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Dermatology clinics (Guys and St Thomas' Hospital and University Hospitals Birmingham) and community (healthy volunteers)
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Able to provide written informed consent prior to performing any protocol-related procedures, including screening. * Adults (≥18 years) with confirmed diagnosis of inflammatory skin disease (defined as any skin disease with an inflammatory component, including but not limited to, genetic skin disease, such as EB), OR * Adults age (≥18 years) without skin or systemic disease. Exclusion Criteria: * Inability to give written informed consent. * Participants who have received topical corticosteroids to sites of biopsies (inflamed area of skin) for at least 2 weeks prior to tissue sampling. * Inability to participate in study-specific procedures. * Participants who are pregnant (confirmed on a positive urine pregnancy test) or breastfeeding * Enrolment in any interventional study with systemic treatment within 3 months prior to baseline biopsy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Inflammatory skin conditions are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.